ClinicalTrials.gg
CompletedNCT00814515Updated Jul 16, 2010

Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome

A Phase 3 interventional study of NOVA22007 (Ciclosporin 0.1%) and NOVA22007 in Moderate to Severe Dry Eye Syndrome, sponsored by Santen SAS. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-16.

Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing cyclosporine in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. Cyclosporine · Lymphoma, Follicular.

Planned enrollment
Largest of 19
482 · median 20
Started
2007
with 2 others
Phase 3
3 of 20
none open now
Registered
19th of 20
by date
Lead sponsor
1 of 20
Santen SAS

Among the 20 studies testing cyclosporine in Lymphoma, Follicular, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2007, is one of 3 in phase 3, and was the 19th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 20 studies testing cyclosporine in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing cyclosporine in Lymphoma, Follicular as a file.
02

Study summary

A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome

03

Conditions studied

  • Moderate to Severe Dry Eye Syndrome

Keywords

  • Moderate
  • Severe
  • Dry
  • Eye
  • Ciclosporin
  • Cyclosporine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 18 years of age or greater.
  • At baseline, moderate to severe dry eye condition persisting despite conventional management.

Exclusion criteria

Exclusion Criteria:

  • Presence or history of any systemic or ocular disorder or condition, including ocular surgery, trauma or disease that could possibly interfere with the interpretation of study results.
  • Any relevant ocular anomaly interfering with the ocular surface, including post radiation keratitis, Stevens-Johnson syndrome, corneal ulcer history or concomitant corneal ulcer of infectious origin, etc.
  • Any other ocular diseases requiring topical ocular treatment during the study period.
  • Patient who has participated in a clinical trial with a new active substance during the past month before study entry.
  • Participation in another clinical study at the same time as the present study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
482 participants (estimated)

Study arms

  • Active comparator
    1

    Ciclosporin 0.1%

    Drug: NOVA22007 (Ciclosporin 0.1%)

  • Placebo comparator
    2

    Vehicle

    Drug: NOVA22007

Interventions

06

What researchers measure

Primary outcomes

  1. Corneal fluorescein staining (on modified Oxford scale)

    Time frame: Approximately 26 weeks

  2. Patient's global score of all symptoms of ocular discomfort unrelated to study medication instillation, using a visual analog scale (VAS) ranging from 0%-100%

    Time frame: Approximately 26 weeks

Secondary outcomes

  1. • Ocular Symptom Disease Index© (OSDI©) questionnaire • Percentage of complete responder to corneal fluorescein staining (on modified Oxford scale), i.e. with corneal staining score =0 • Patient's score of each symptom of ocular discomfort unrelated to

    Time frame: Approximately 26 weeks

07

Study locations

1 site
  • Hôpital des XV-XX
    Paris, Île-de-France 75012, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2008
First posted
Dec 25, 2008
Start
Sep 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Last update
Jul 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00814515
Lead sponsor
Santen SAS
First posted
Dec 25, 2008
Start date
Sep 2007
Primary completion
Sep 2009
Completion
Sep 2009
Last update
Jul 16, 2010

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion